DVX201 Clin1 COVID-19, Clin1 AML/MDS; undisclosed Clin0 multiple cancers; undisclosed RD oncology
Deverra Therapeutics is creating allogeneic universal donor cell therapies to treat cancer and other life-threatening diseases. Universal cell therapies are attractive since they eliminate the risk of immune rejection for all patient receivers. To develop such therapies, Deverra is using their versatile platform technology that uses sustainable, healthy donor umbilical cord blood cells. From these cells, Deverra can generate a plethora of cell types which can then be used in a diverse pipeline of cell therapies for multiple indications. Deverra’s lead candidate, Dilanubicel, is an adjuvant, non-engrafting hematopoietic stem and progenitor cell immunotherapy to treat patients with acute myeloid leukemia.